Dr. Justin F. Klamerus

Gaylord, MI
Specialties:Oncology
OverviewInsuranceLocationsClinical Research

Overview

Justin Klamerus is an Oncologist in Gaylord, Michigan.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MI
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  McLaren Health
  •  Humana

Locations

701 N Otsego Ave, Gaylord, MI 49735
989-731-7760

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2024
Intervention Type: Drug
Study Phase: Phase 3
S1013: A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18(FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities
S1013: A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18(FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities
Enrollment Status: Completed
Publish Date: December 15, 2022
Intervention Type: Procedure
View 4 Less Clinical Trials

6 Total Publications

Do Patients and Oncologists Discuss the Cost of Cancer Treatment? An Observational Study of Clinical Interactions Between African American Patients and Their Oncologists.
Do Patients and Oncologists Discuss the Cost of Cancer Treatment? An Observational Study of Clinical Interactions Between African American Patients and Their Oncologists.
Journal: Journal of oncology practice
Published: December 14, 2016
Similar Doctors
Expertise in
44
conditions
Dr. Peter C. Kohler
Oncology
Expertise in
44
conditions
Dr. Peter C. Kohler
Oncology

Munson Medical Center

1400 Medical Campus Dr, 
Traverse City, MI 
 (51.0 mi)
231-935-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Peter Kohler is an Oncologist in Traverse City, Michigan. Dr. Kohler is highly rated in 44 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Familial Prostate Cancer, Breast Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Kohler is currently accepting new patients.

Expertise in
17
conditions
Dr. Jennifer L. Lawhorn
Hematology Oncology | Hematology | Oncology
Expertise in
17
conditions
Dr. Jennifer L. Lawhorn
Hematology Oncology | Hematology | Oncology

Munson Healthcare Otsego Memorial Hospital

701 N Otsego Ave, Mhc Omh Cancer And Infusion Center, 
Gaylord, MI 
989-731-7760
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jennifer Lawhorn is a Hematologist Oncology specialist and a Hematologist in Gaylord, Michigan. Dr. Lawhorn is highly rated in 17 conditions, according to our data. Her top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Familial Pancreatic Cancer, and Colorectal Cancer. Dr. Lawhorn is currently accepting new patients.

Expertise in
35
conditions
Dr. David P. Michelin
Gynecologic Oncology | Surgical Oncology | Oncology
Expertise in
35
conditions
Dr. David P. Michelin
Gynecologic Oncology | Surgical Oncology | Oncology

Munson Medical Center

217 S Madison St, 
Traverse City, MI 
 (50.9 mi)
231-392-8400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Michelin is a Gynecologic Oncologist and a Surgical Oncologist in Traverse City, Michigan. Dr. Michelin is highly rated in 35 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Vulvar Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, and Oophorectomy. Dr. Michelin is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition

We do not have enough information to identify the Areas of Expertise for this provider.

Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile